Syndax Grants Inducement Options for Up to 213,300 Shares | SNDX Stock News
Syndax Pharmaceuticals (SNDX) announced the grant of inducement stock options for up to 213,300 common shares to nine new employees on October 1, 2026. These awards, issued under the company's 2023 Inducement Plan, will vest over four years, with 25% on the first anniversary and the remainder vesting monthly over 36 months, subject to continued service. This move creates potential dilution but is a common practice for attracting new talent.
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Cross Below Fifty Day Moving Average - Here's What Happened
Syndax Pharmaceuticals (NASDAQ:SNDX) saw its shares fall below their 50-day moving average, trading at $18.22 after reaching a low of $18.05, below the $19.33 average. Despite this, analysts largely maintain a "Moderate Buy" consensus with an average price target of $41.80, though some targets have been lowered. The company also reported missing quarterly earnings and revenue estimates, alongside significant insider selling and institutional investment changes.
Cash flow from investing activities of Syndax Pharmaceuticals Inc – HAN:1T3
This article provides a financial update for Syndax Pharmaceuticals Inc, specifically focusing on its cash flow from investing activities. It lists the company's ticker symbol HAN:1T3 on the Hannover Stock Exchange and indicates that the market is currently closed with no trades. The content highlights financial data sourced from ICE Data Services and FactSet.
Enterprise value of Syndax Pharmaceuticals Inc – HAN:1T3
This article provides the enterprise value of Syndax Pharmaceuticals Inc (HAN:1T3) listed on the Hannover Stock Exchange. The current market status indicates that the market is closed with no trades recorded. The page includes general financial information and market data for the company.
Syndax Pharmaceuticals, Inc. (SNDX) Stock Price, News, Quote & History
This Yahoo Finance page provides detailed financial information for Syndax Pharmaceuticals, Inc. (SNDX). It includes current stock price, after-hours trading, historical data, key performance indicators, an overview of the company's biopharmaceutical products, and analyst insights. The company is focused on developing therapies for cancer, with lead candidates Revuforj and Niktimvo.
Syndax Pharmaceuticals rated 'Strong Buy' on label expansion and revenue growth for Revuforj and Niktimvo.
Syndax Pharmaceuticals has received a "Strong Buy" rating due to FDA approvals and label expansion for its key drugs, Revuforj and Niktimvo. Revuforj is approved for relapsed/refractory mNPM1 AML, while Niktimvo, approved for cGVHD, is being explored for IPF and first-line cGVHD, with significant Phase 2 data anticipated in Q4 2026. The company boasts $575 million in liquidity and growing revenues, positioning it for profitability without immediate capital raises.
Syndax: 'Strong Buy' Revuforj Pipeline Growth And Niktimvo Q4 2026 Data Releases (SNDX)
Syndax Pharmaceuticals (SNDX) is rated a "Strong Buy" due to the anticipated label expansion and revenue growth of its drugs, Revuforj and Niktimvo. Revuforj has FDA approval for r/r mNPM1 AML and is being developed for 1st-line AML, while Niktimvo, approved for cGVHD, is progressing into IPF and 1st-line cGVHD, with key Phase 2 data expected in Q4 2026. The company is in a strong financial position with $575M in liquidity and is projected to achieve profitability without needing to raise additional capital soon.
Syndax Pharmaceuticals poised for growth with promising Revuforj data and strong pipeline.
Syndax Pharmaceuticals is expected to grow significantly due to its drugs Revuforj and Niktimvo, with Revuforj alone projected to achieve over $2 billion in peak U.S. sales. Recent trial data for Revuforj in acute myeloid leukemia (AML) show high response rates, supporting ongoing phase 3 trials and real-world use. The company also has a strong pipeline of next-generation inhibitors, making it a compelling long-term investment despite clinical and competitive risks.
H.C. Wainwright Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $38
H.C. Wainwright analyst Andres Y. Maldonado has reiterated a Buy rating for Syndax Pharmaceuticals (SNDX.US), maintaining a target price of $38. According to TipRanks data, Maldonado boasts a 51.7% success rate and a 33.5% average return over the past year. This endorsement suggests continued confidence in Syndax Pharmaceuticals' financial outlook.
Bank of America Corp DE Purchases New Shares in Syndax Pharmaceuticals, Inc. $SNDX
Bank of America Corp DE has acquired a new position in Syndax Pharmaceuticals, Inc., purchasing over 4 million shares valued at approximately $88.4 million during the second quarter. This move makes Bank of America a significant holder, owning about 4.57% of Syndax Pharmaceuticals. Despite the acquisition, Syndax Pharmaceuticals reported a quarterly loss and revenue that missed analyst estimates, though analysts maintain a "Moderate Buy" consensus for the stock.
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Average Recommendation of "Moderate Buy" from Brokerages
Eleven brokerages have issued a "Moderate Buy" rating for Syndax Pharmaceuticals (NASDAQ:SNDX), with an average 12-month price target of $42.30, significantly above its current trading price of $18.18. Despite this bullish analyst sentiment, the company recently missed quarterly earnings and revenue estimates, though revenue increased 91.8% year-over-year. Insider selling by the CEO in July also saw a reduction in his ownership.
WINTON GROUP Ltd Has $1.67 Million Position in Syndax Pharmaceuticals, Inc. $SNDX
WINTON GROUP Ltd significantly increased its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 642.7% in the second quarter, bringing its total holdings to 76,500 shares valued at approximately $1.67 million. Despite the company reporting a wider-than-expected quarterly loss and revenue miss, analysts maintain a "Moderate Buy" rating with an average price target of $42.30. Several institutional investors also initiated or expanded their positions in Syndax Pharmaceuticals, while CEO Michael Metzger sold a portion of his shares.
Squarepoint Ops LLC Boosts Holdings in Syndax Pharmaceuticals, Inc. $SNDX
Squarepoint Ops LLC significantly increased its stake in Syndax Pharmaceuticals Inc. by 104% in the second quarter, now owning 370,317 shares valued at $8.1 million. Despite this increased institutional interest, the company reported a quarterly loss and revenue below analyst expectations, and several firms have lowered their price targets, although the consensus rating remains "Moderate Buy." CEO Michael Metzger also sold a substantial number of shares in July.
Legal & General Group Plc Takes Position in Syndax Pharmaceuticals, Inc. $SNDX
Legal & General Group Plc has acquired a significant stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) during the second quarter, purchasing 65,483 shares valued at approximately $1.43 million. This comes as several other institutional investors also adjusted their positions in the company. Despite Syndax Pharmaceuticals reporting a quarterly loss that missed analyst expectations, revenue increased by 91.8% year-over-year, and analysts generally maintain a "Moderate Buy" rating with a target price significantly above the current trading price.
Syndax Pharmaceuticals Stock Price Forecast. Should You Buy SNDX?
StockInvest.us has downgraded Syndax Pharmaceuticals Inc (SNDX) from a "Buy" to a "Sell Candidate" as of September 8, 2026, due to recent negative price movements and technical signals. The stock fell by 3.02% on the last trading day, and while it finds support at $19.92, short and long-term moving averages indicate a negative forecast. The platform predicts the stock will trade between $18.77 and $24.44 in the next three months.
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals announced that it granted inducement awards to nineteen new employees to purchase up to 175,000 shares of common stock under its 2023 Inducement Plan. These stock options will vest over four years, with a portion vesting on the one-year anniversary and the remainder monthly thereafter, contingent on continued employment. The company is a commercial-stage biopharmaceutical firm focused on innovative cancer therapies.
Nineteen new employees get options to buy up to 175,000 Syndax shares. The options vest over four years.
Syndax Pharmaceuticals (SNDX) has granted inducement stock options for up to 175,000 shares of common stock to nineteen new employees on September 1, 2026, under its 2023 Inducement Plan. The options will vest over four years, with 25% vesting after the first year and the remaining 75% vesting in equal monthly installments over the subsequent 36 months, contingent on continuous employment. This move aims to align employee interests with the company's growth.
Syndax Pharmaceuticals Inc. (SNDX) Peer Comparison – Compare with Others
This article provides a detailed financial comparison of Syndax Pharmaceuticals Inc. (SNDX) with its peers in the healthcare and biotechnology sector, including Medpace Holdings, Ascendis Pharma A/S, Exelixis, and Madrigal Pharmaceuticals. It presents various financial metrics such as market cap, revenue, net profit, P/E ratio, and solvency ratios to allow for a comprehensive peer analysis. The data covers income statements, liabilities, assets, cash flow, and key profitability, growth, valuation, and operating efficiency ratios for each company.
Syndax Announces Participation in September Investor Conferences
Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) announced that its CEO, Michael A. Metzger, and other management team members will participate in two upcoming investor conferences in September 2026. These include the Citi 2026 Biopharma Back to School Conference on September 10 and the H.C. Wainwright 28th Annual Global Investment Conference on September 15, both featuring fireside chats. Webcasts of these events will be available on the company's website.
Pale Fire Capital SE Sells 158,910 Shares of Syndax Pharmaceuticals, Inc. $SNDX
Pale Fire Capital SE reduced its stake in Syndax Pharmaceuticals Inc. by 55.9% in the second quarter, selling 158,910 shares and retaining 125,550 shares valued at approximately $2.75 million. This divestment occurred as Syndax reported a quarterly loss of $0.55 per share, missing analyst estimates, despite a 91.8% year-over-year revenue increase. Despite these results, Wall Street analysts maintain a "Moderate Buy" consensus rating for SNDX with an average price target of $41.55.
Two talks by Syndax executives will be webcast live from New York in September.
Syndax Pharmaceuticals (Nasdaq:SNDX) will participate in two investor conferences in September 2026: the Citi 2026 Biopharma Back to School Conference on September 10 and the H.C. Wainwright 28th Annual Global Investment Conference on September 15. CEO Michael A. Metzger and other management team members will conduct fireside chats, which will be webcast live and available for replay on Syndax’s investor website. The article also provides details on recent stock performance, key financial figures, and historical events related to SNDX.
Alyeska Investment Group L.P. Acquires Shares of 308,507 Syndax Pharmaceuticals, Inc. $SNDX
Alyeska Investment Group L.P. recently acquired a significant stake of 308,507 shares in Syndax Pharmaceuticals, valued at approximately $6.74 million, joining other institutional investors in increasing their positions. Despite missing revenue and EPS estimates in its latest quarterly report, Syndax maintains a "Moderate Buy" consensus rating from analysts with an average price target of $41.55. However, insiders have been net sellers of the stock, offloading nearly 97,900 shares in the last 90 days.
Syndax Announces Participation in September Investor Conferences
Syndax Pharmaceuticals announced its CEO and management team will participate in two upcoming investor conferences in September 2026. These include the Citi 2026 Biopharma Back to School Conference and the H.C. Wainwright 28th Annual Global Investment Conference, both featuring fireside chats. Webcasts of these presentations will be available on the company's website.
Syndax Announces Participation in September Investor Conferences
Syndax Pharmaceuticals announced that its CEO, Michael A. Metzger, and other management team members will participate in two upcoming investor conferences in September 2026. These include the Citi 2026 Biopharma Back to School Conference and the H.C. Wainwright 28th Annual Global Investment Conference, both featuring fireside chats. Webcasts of these presentations will be available on the company's website.
Syndax Announces Participation in September Investor Conferences
Syndax Pharmaceuticals, Inc. announced its CEO and management team will participate in two upcoming investor conferences in September 2026: the Citi 2026 Biopharma Back to School Conference and the H.C. Wainwright 28th Annual Global Investment Conference. Live webcasts and replays of the fireside chats will be available on the company's website. Syndax is a commercial-stage biopharmaceutical company focused on innovative cancer therapies, including its FDA-approved drugs Revuforj® and Niktimvo™.
Syndax Announces Participation in September Investor Conferences
Syndax Pharmaceuticals (Nasdaq: SNDX) announced that its CEO and management team will participate in two upcoming investor conferences in September 2026: the Citi 2026 Biopharma Back to School Conference and the H.C. Wainwright 28th Annual Global Investment Conference. Live webcasts of the fireside chats will be available on the company's website. Syndax is a commercial-stage biopharmaceutical company focused on innovative cancer therapies, including its FDA-approved drugs Revuforj® and Niktimvo™.
Man Group plc Takes $4.67 Million Position in Syndax Pharmaceuticals, Inc. $SNDX
Man Group plc has acquired a new position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) worth approximately $4.67 million, purchasing 213,703 shares. This comes amidst significant insider selling, with CEO Michael A. Metzger and CMO Nicholas A.J. Botwood reducing their holdings. Despite these insider transactions and missing recent quarterly EPS and revenue estimates, analysts largely maintain a "Moderate Buy" rating for Syndax, with a consensus target price of $41.55.
BlackRock Inc. Makes New Investment in Syndax Pharmaceuticals, Inc. $SNDX
BlackRock Inc. has made a significant new investment in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX), acquiring over 9 million shares valued at approximately $197.2 million, giving it a 10.18% stake. This investment comes despite Syndax reporting a quarterly loss and missing revenue expectations, though its revenue saw a substantial year-over-year increase. Analysts maintain a "Moderate Buy" consensus for the stock, with an average price target considerably higher than its current trading price.
864,986 Shares in Syndax Pharmaceuticals, Inc. $SNDX Acquired by Palo Alto Investors LP
Palo Alto Investors LP acquired 864,986 shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) for approximately $18.9 million in the second quarter, making it their 14th largest holding. Despite recent insider selling and the company missing earnings estimates, analysts maintain a "Moderate Buy" consensus rating with a target price of $41.55. Other institutional investors like BlackRock Inc. and Bank of America Corp DE also established significant positions in Syndax Pharmaceuticals.
Ieq Capital LLC Takes Position in Syndax Pharmaceuticals, Inc. $SNDX
Ieq Capital LLC has acquired a new position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) during the second quarter, purchasing 54,835 shares valued at approximately $1.2 million. This move is part of a broader trend of institutional investment in Syndax, despite the company reporting a quarterly loss of $0.55 per share, missing estimates. Analysts maintain a "Moderate Buy" rating for SNDX with an average price target of $41.55, reflecting optimism about the company's future despite recent financial performance and insider selling.
Seven Fleet Capital Management LP Invests $1.65 Million in Syndax Pharmaceuticals, Inc. $SNDX
Seven Fleet Capital Management LP recently acquired 77,930 shares of Syndax Pharmaceuticals (NASDAQ:SNDX) for approximately $1.65 million. Other major institutions like BlackRock, Vanguard, and Goldman Sachs have also increased their positions. Despite insider sales totaling $2.12 million and missing quarterly EPS and revenue estimates, analysts maintain a "Moderate Buy" rating with an average target price of $41.55.
Trails Edge Capital Partners LP Buys Shares of 1,110,000 Syndax Pharmaceuticals, Inc. $SNDX
Trails Edge Capital Partners LP has acquired a new stake of 1,110,000 shares in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) during the second quarter, valued at approximately $24.26 billion. This investment makes Syndax Pharmaceuticals the 12th largest position in Trails Edge Capital Partners LP's portfolio, representing about 3.9% of their total holdings. Other institutional investors also increased their stakes, while several insiders, including the CEO and CMO, sold significant amounts of company stock.
Elmind Capital LP Buys Shares of 1,855,000 Syndax Pharmaceuticals, Inc. $SNDX
Elmind Capital LP has acquired a new position of 1,855,000 shares in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX), valued at approximately $40.55 billion, making it their second largest holding. Other institutional investors like Hsbc Holdings PLC and Mirae Asset Global Investments Co. Ltd. also adjusted their stakes in the company. Syndax Pharmaceuticals recently reported an EPS of ($0.55), missing analyst estimates, and has a current market cap of $1.77 billion.
Parkman Healthcare Partners LLC Purchases New Shares in Syndax Pharmaceuticals, Inc. $SNDX
Parkman Healthcare Partners LLC has acquired 877,256 shares of Syndax Pharmaceuticals, Inc. (SNDX) valued at approximately $19.2 million, making it their 19th largest holding and representing 0.99% of Syndax's outstanding stock. Other institutional investors also increased or initiated positions in Syndax, despite the company reporting a quarterly loss that missed analyst estimates and insider stock sales totaling $2.1 million. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $41.55.
Algert Global LLC Has $22.98 Million Holdings in Syndax Pharmaceuticals, Inc. $SNDX
Algert Global LLC increased its stake in Syndax Pharmaceuticals (NASDAQ:SNDX) by 13.2% in the second quarter, bringing its total holdings to 1,051,465 shares valued at $22.98 million. Other institutional investors also adjusted their positions in the company, while several Wall Street analysts maintained "buy" or "overweight" ratings, with a consensus price target of $41.55. Recent insider transactions include sales by the CEO and CMO, and the company reported a quarterly EPS of ($0.55), missing consensus estimates.
SYNDAX PHARMACEUTICALS, INC. : UBS CUTS TARGET PRICE TO $33 FROM $37
UBS has cut its target price for Syndax Pharmaceuticals Inc. (SNDX.O) from $37 to $33. This update was reported by Reuters on August 21, 2026, and is available on Bitget News.
UBS Adjusts Price Target on Syndax Pharmaceuticals to $33 From $37, Keeps Buy Rating
UBS has revised its price target for Syndax Pharmaceuticals (SNDX) to $33, down from $37, while maintaining a Buy rating on the stock. This adjustment reflects a change in the financial outlook or valuation model for the pharmaceutical company by the investment bank. Despite the lowered price target, the continued Buy rating suggests that UBS still sees upside potential for Syndax Pharmaceuticals.
UBS lowers Syndax Pharmaceuticals price target on revenue outlook
UBS has lowered its price target for Syndax Pharmaceuticals (NASDAQ:SNDX) to $33 from $37, while maintaining a Buy rating. This adjustment comes after a decline in Revuforj new patient starts in Q2 2026, though the firm anticipates a recovery in new patient starts and increased Revuforj revenue in the second half of 2026 and fiscal year 2027. Despite the revised target, analysts still have a strong buy consensus, and InvestingPro analysis suggests the stock is undervalued given its impressive revenue growth.
SNDX Maintained by UBS -- Price Target Lowered to $33
UBS has maintained a "Buy" rating for Syndax Pharmaceuticals (SNDX) but lowered its price target from $37 to $33, reflecting a more cautious outlook. The company, a clinical-stage biopharmaceutical firm, faces challenges with a low GF Score of 27/100, indicating weak financial health, profitability, and growth potential, despite strong momentum. Investors are advised to be cautious due to the high Price-to-Sales ratio and recent insider selling.
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates
Syndax Pharmaceuticals (SNDX) reported a Q1 loss of $0.48 per share, which was better than the Zacks Consensus Estimate of a $0.59 loss. However, the company missed revenue estimates, posting $64.86 million against an expected $70.00 million. Despite exceeding EPS estimates in three of the last four quarters, the stock has underperformed the S&P 500 year-to-date, and currently holds a Zacks Rank #3 (Hold).
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Average Rating of "Moderate Buy" from Analysts
Thirteen research firms have given Syndax Pharmaceuticals (NASDAQ:SNDX) an average recommendation of "Moderate Buy," with an average 12-month price target of $41.91. Despite missing Q2 earnings and revenue estimates and insider share sales, institutional investors like BlackRock and Vanguard have increased their stakes. The company, focused on developing cancer therapies, maintains a positive outlook from analysts.
When Will Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Breakeven?
This article analyzes when Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is expected to reach breakeven, according to analyst forecasts. It examines the company's current financial position and the timeline projected for profitability.
GSA Capital Partners LLP Purchases New Position in Syndax Pharmaceuticals, Inc. $SNDX
GSA Capital Partners LLP has acquired a new position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX), purchasing 62,775 shares valued at approximately $1.37 million during the second quarter. This move comes as several other institutional investors also increased their holdings in the company. Despite missing revenue and EPS estimates in its latest earnings report, analysts maintain a "Moderate Buy" consensus rating for Syndax Pharmaceuticals, with an average price target of $41.91.
The Technical Signals Behind (SNDX) That Institutions Follow
Stock Traders Daily provides a technical analysis of Syndax Pharmaceuticals Inc. (NASDAQ: SNDX), highlighting a mid-channel oscillation pattern with positive near-term sentiment within a long-term strength context. The analysis details three institutional trading strategies (Position Trading, Momentum Breakout, and Risk Hedging) and offers multi-timeframe signal analysis with specific support and resistance levels. The report also notes an exceptional 58.7:1 risk-reward setup.
SNDX Maintained by JP Morgan -- Price Target Lowered to $40.00
JP Morgan has maintained an "Overweight" rating on Syndax Pharmaceuticals (SNDX) but lowered its price target from $44.00 to $40.00. The company, with a market cap of $1.81 billion, faces challenges indicated by its GF Score™ of 22/100 and a high price-to-sales ratio of 77.2x. Insider activity shows net selling, suggesting caution for investors despite the analyst's "Overweight" rating.
Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $40.00 Price Target at JPMorgan Chase & Co.
JPMorgan Chase & Co. has lowered its price target for Syndax Pharmaceuticals (NASDAQ:SNDX) from $44.00 to $40.00, while maintaining an "overweight" rating. Despite the reduced target, the average analyst rating for SNDX remains "Moderate Buy" with a consensus price target of $41.91, suggesting significant upside potential. The company recently missed earnings estimates, reporting an adjusted loss of $0.55 per share and revenue of $72.79 million against expectations.
Syndax Pharmaceuticals (SNDX) Stock Looks Stretched As Its 63% Run Continues
Syndax Pharmaceuticals (SNDX) has seen a 63.5% gain over the past year, but its current share price of US$20.40 appears stretched based on valuation metrics. Despite pipeline progress, the stock's P/S ratio of 7.2x is above its tailored fair P/S of 3.4x, suggesting it may be overvalued relative to its fundamentals. The company's future performance hinges on its oncology pipeline's ability to translate into revenue that justifies the current investor optimism.
Hennion & Walsh Asset Management Inc. Increases Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX
Hennion & Walsh Asset Management Inc. significantly increased its stake in Syndax Pharmaceuticals, Inc. by 59.6% in Q2 2026, now holding 342,883 shares valued at approximately $7.5 million. This increase comes alongside other institutional investments and recent insider stock sales by the CMO and CEO. Despite missing consensus earnings estimates for the quarter, analysts maintain a "Moderate Buy" rating with a consensus price target of $42.36, though some have reduced future earnings forecasts, anticipating a longer path to profitability.
Long term debt to total assets ratio of Syndax Pharmaceuticals Inc – HAM:1T3
This page provides financial data for Syndax Pharmaceuticals Inc (HAM:1T3), specifically focusing on its long-term debt to total assets ratio. It appears to be a financial data portal, offering an overview of the company's financials, although the specific ratio value is not displayed in the provided content. The page also includes navigation for various market data, community features, and tools offered by TradingView.
Bank of America Corp DE Decreases Position in Syndax Pharmaceuticals, Inc. $SNDX
Bank of America Corp DE reduced its stake in Syndax Pharmaceuticals, Inc. by 9.8% in the first quarter, selling over 460,000 shares but still retaining a significant holding worth about $99.3 million. Despite this reduction, other institutional investors like Vanguard, Orbimed Advisors, Qube Research, and Adage Capital increased their positions. Syndax Pharmaceuticals reported a quarterly loss and revenue miss, though analysts maintain a "Moderate Buy" rating with an average price target of $42.36, even as some forecasts for future profitability have been lowered.
